Uretritis Gonore

01Pathophysiology

Neisseria gonorrhoeae is a gram-negative diplococcus that demonstrates a strong tropism for non-ciliated columnar and cuboidal epithelial cells. This tropism explains why the organism preferentially infects the urethra, endocervix, rectum, pharynx, and conjunctiva, all of which are lined by this type of epithelium. The stratified squamous epithelium of the adult vagina is naturally resistant, which is why vaginitis is uncommon in adult women with gonorrhea (though prepubertal girls, who have thinner vaginal epithelium, can develop gonococcal vaginitis).
Attachment to mucosal surfaces is mediated by pili (fimbriae) and opacity-associated (Opa) proteins. Once attached, the organism is endocytosed into epithelial cells and transported to the subepithelial space. The bacterial lipooligosaccharide (LOS) on the outer membrane acts as a potent endotoxin, triggering a robust neutrophilic inflammatory response. This intense influx of neutrophils is directly responsible for the hallmark finding: thick, purulent discharge. The more vigorous the neutrophil response, the more purulent the discharge appears. This is the core connection between mechanism and presentation that vignettes test: purulent discharge equals intense neutrophilic inflammation driven by LOS.
A critical concept for exam purposes is immune evasion. N. gonorrhoeae undergoes antigenic variation of its pili and Opa proteins, constantly changing its surface antigens. It also produces IgA protease, which cleaves secretory IgA at mucosal surfaces and undermines local immune defense. These evasion mechanisms explain two testable facts: (1) patients do not develop lasting protective immunity, making reinfection common, and (2) no effective vaccine exists.
Ascending infection in women occurs when the organism spreads from the endocervix through the endometrium to the fallopian tubes, causing pelvic inflammatory disease (PID). The resulting salpingitis and tubal scarring are the primary mechanisms behind infertility, ectopic pregnancy, and chronic pelvic pain as long-term sequelae. Disseminated gonococcal infection (DGI) occurs when the organism enters the bloodstream, typically in patients with complement deficiencies (particularly terminal complement components C5 through C9, the membrane attack complex). This is a high-yield association: a young patient with recurrent Neisseria infections (meningococcal or gonococcal) should prompt evaluation for terminal complement deficiency.

02Classification and Clinical Manifestation

03Diagnostic Workup

NAAT is the best initial test and the standard of care for diagnosing gonococcal urethritis at all anatomic sites. It is the most sensitive method available and can detect both N. gonorrhoeae and C. trachomatis simultaneously from a single specimen (a urine sample or swab). Because of its high sensitivity, NAAT has largely replaced culture as the primary diagnostic tool.
Gram stain of urethral discharge plays a supportive role. In a symptomatic male presenting with purulent discharge, finding gram-negative intracellular diplococci within polymorphonuclear leukocytes on Gram stain provides a rapid presumptive diagnosis and justifies immediate empiric treatment. However, this test performs poorly in women and in asymptomatic patients, so it should never be relied upon as the sole diagnostic method in those populations.
Culture on Thayer-Martin agar is the most accurate (confirmatory) test and remains essential for antimicrobial susceptibility testing. This is the test you order when treatment failure is suspected or when public health surveillance of resistance patterns is needed. Thayer-Martin is a chocolate agar supplemented with antibiotics (vancomycin to kill gram-positive organisms, colistin to kill gram-negative organisms other than Neisseria, nystatin to kill fungi, and trimethoprim to inhibit swarming Proteus). The medium grows Neisseria while suppressing normal flora. Remember that the organism requires a CO2-enriched environment and is fastidious, so cultures must be transported and plated promptly.
Always screen for co-infections. The rate of concurrent chlamydial infection in patients with gonorrhea is high enough (up to 20 to 40%) that empiric co-treatment for chlamydia is standard practice unless NAAT definitively excludes it. All patients should also be tested for syphilis and HIV.

04Management and Treatment

Acute treatment of uncomplicated gonococcal urethritis centers on a single intramuscular injection of Ceftriaxone 500 mg. This is the first-line and only recommended injectable cephalosporin. Patients weighing 150 kg or more should receive 1 g IM. A key update in current guidelines is that azithromycin 1 g is no longer routinely added as dual therapy for uncomplicated genital/rectal gonorrhea in non-pregnant patients. The previous recommendation for routine dual therapy was driven by concerns about emerging cephalosporin resistance, but current evidence supports ceftriaxone monotherapy when chlamydia has been excluded.
When chlamydial co-infection has not been excluded (which is the case in most clinical scenarios and most exam vignettes), the next best step is to add Doxycycline 100 mg PO twice daily for 7 days. This is the standard co-treatment regimen. In pregnancy, doxycycline is absolutely contraindicated (teratogenic, category D), and azithromycin 1 g PO single dose replaces it.
For patients with a confirmed severe cephalosporin allergy (anaphylaxis, not just a mild rash), the alternative regimen is Gentamicin 240 mg IM plus Azithromycin 2 g PO, both given as single doses.
Fluoroquinolones (ciprofloxacin, levofloxacin) are no longer recommended for gonococcal infections due to widespread resistance. This is one of the most commonly tested "wrong answer" traps.
Partner management is a critical component. All sexual partners from the preceding 60 days must be evaluated, tested, and treated. Expedited partner therapy (providing a prescription for the partner without a clinical evaluation) is permitted in certain jurisdictions when the partner is unlikely to seek care. All patients should abstain from sexual activity for 7 days after treatment and until all partners have been treated.
Test of cure (repeat NAAT performed no sooner than 7 to 14 days after treatment) is recommended for pharyngeal gonorrhea (which is harder to eradicate) and in cases of suspected treatment failure. For uncomplicated urogenital gonorrhea, test of cure is not routinely required but retesting at 3 months is recommended for all patients because of the high rate of reinfection.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students miss questions on gonococcal urethritis is by failing to co-treat for chlamydia. Exam vignettes will often present a classic gonorrhea scenario and offer answer choices that include ceftriaxone alone versus ceftriaxone plus doxycycline. If the question stem does not explicitly state that chlamydia has been excluded by testing, the correct answer is almost always dual therapy. This tests your understanding that co-infection rates are clinically significant and that empiric coverage is standard of care.
A second common trap involves fluoroquinolones. Ciprofloxacin was historically a first-line treatment for gonorrhea, and it still appears as a tempting answer choice. Current guidelines have removed fluoroquinolones entirely from the gonococcal treatment algorithm due to high resistance rates. Always choose ceftriaxone over ciprofloxacin.
Another frequently tested concept is the association between recurrent Neisseria infections and terminal complement deficiency. When a vignette describes a patient with a second or third episode of gonococcal (or meningococcal) infection, the expected next step is to evaluate for complement deficiency (C5 through C9). The membrane attack complex is essential for killing encapsulated gram-negative organisms like Neisseria, and its absence predisposes to recurrent bacteremia and disseminated infection.
Watch for the epididymitis age rule. A young sexually active man under 35 with unilateral scrotal pain and swelling should be treated empirically for gonorrhea and chlamydia. The same presentation in a man over 35 points toward gram-negative enteric organisms like E. coli, and the treatment shifts to fluoroquinolones or trimethoprim-sulfamethoxazole.
Finally, do not confuse the dermatitis-arthritis syndrome of DGI with reactive arthritis. Both involve joint pain and urethritis. The discriminator is that DGI produces pustular skin lesions on the extremities and positive joint/blood cultures, while reactive arthritis produces sterile joint fluid, conjunctivitis, and is HLA-B27 associated. If the question describes skin lesions plus tenosynovitis in a sexually active patient, think DGI first.
The core competency being tested is your ability to recognize the classic purulent presentation, commit to the correct empiric regimen (ceftriaxone plus doxycycline), and resist outdated or incorrect treatment choices that exploit knowledge of prior guidelines.